Synapse - Works

Results (988)

Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: A meta-analysis

Journal Article

Avet-Loiseau, H.; Ludwig, H.; Landgren, O.; Paiva, B.; Morris, C.; Yang, H.; Zhou, K.; Ro, S.; Mateos, M. V.
Clinical Lymphoma, Myeloma and Leukemia (2020)

Fulltext@MSK | Save

Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis

Journal Article

Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
Biology of Blood and Marrow Transplantation (2020)

Fulltext@MSK | Save

Presalvage international staging system stage and other important outcome associations in CD34(+)-selected allogeneic hematopoietic stem cell transplantation for multiple myelomas

Journal Article

Bryant, A. R.; Hilden, P.; Giralt, S.; Chung, D. J.; Maloy, M.; Landau, H.; Landgren, O.; Scordo, M.; Shah, G.; Smith, E. L.; more...
Biology of Blood and Marrow Transplantation (2020)

Fulltext@MSK | Save

Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors

Journal Article

Hultcrantz, M.; Modlitba, A.; Vasan, S. K.; Sjölander, A.; Rostgaard, K.; Landgren, O.; Hjalgrim, H.; Ullum, H.; Erikstrup, C.; Kristinsson, S. Y.; more...
Thrombosis Research (2020)

Fulltext@MSK | Save

Monoclonal gammopathies

Book Section

Murata, K.; McCash, S.; Landgren, C. O.
In Rich, R. R.; Fleisher, T. A.; Shearer, W. T.; Schroeder, H. W. Jr; Frew, A. J.; Weyand, C. M (Eds.) Clinical Immunology: Principles and Practice. 5th ed (2019)

Fulltext@MSK | Save

Peripheral neuropathy in MGUS and progression to amyloid light-chain amyloidosis: A population-based study including 15,351 MGUS cases

Meeting Abstract

Rognvaldsson, S.; Turesson, I.; Bjorkholm, M.; Landgren, O.; Kristinsson, S. Y.
Blood (2019)

Fulltext@MSK | Save

A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis

Meeting Abstract

Sanchez, L.; Landau, H. J.; Rosenbaum, C. A.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
Blood (2019)

Fulltext@MSK | Save

Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis

Meeting Abstract

Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
Blood (2019)

Fulltext@MSK | Save

Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Raje, N. S.; Jakubowiak, A.; Gasparetto, C.; Cornell, R. F.; Krupka, H. I.; Navarro, D.; Forgie, A. J.; Udata, C.; Basu, C.; Chou, J.; more...
Blood (2019)

Fulltext@MSK | Save

VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis

Meeting Abstract

Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
Blood (2019)

Fulltext@MSK | Save